Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials

被引：12
|
作者：
Allan, John N.
Shanafelt, Tait
Wiestner, Adrian
Moreno, Carol
O'Brien, Susan M.
Braggio, Esteban
Liu, Emily
Dean, James P.
Lai, Dominic
Ahn, Inhye E.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134431
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia:: results from a detailed genetic characterization with long-term follow-up
    Zenz, Thorsten
    Kroeber, Alexander
    Scherer, Katrin
    Haebe, Sonja
    Buehler, Andreas
    Benner, Axel
    Denzel, Tina
    Winkler, Dirk
    Edelmann, Jennifer
    Schwaenen, Carsten
    Doehner, Hartmut
    Stilgenbauer, Stephan
    BLOOD, 2008, 112 (08) : 3322 - 3329
  • [22] Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency
    Rigolin, Gian Matteo
    Olimpieri, Pier Paolo
    Summa, Valentina
    Celant, Simone
    Scarfo, Lydia
    Tognolo, Lucia
    Ballardini, Maria Pia
    Urso, Antonio
    Sessa, Mariarosaria
    Gambara, Silvia
    Cura, Francesca
    Fortini, Monica
    Ghia, Paolo
    Cuneo, Antonio
    Russo, Pierluigi
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [23] LONG-TERM FOLLOW-UP OF A PHASE IB TRIAL OF IDELALISIB IN COMBINATION WITH CHEMOIMMUNOTHERAPY (CIT) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CLL INCLUDING PATIENTS WITH DEL17P/TP53 MUTATION
    Barrientos, J.
    Coutre, S.
    De Vos, S.
    Flinn, I.
    Wagner-Johnston, N.
    Schreeder, M.
    Sharman, J.
    Boyd, T.
    Rai, K.
    Leonard, J.
    Sorensen, B.
    Viggiano, A.
    Jahn, T.
    Furman, R.
    HAEMATOLOGICA, 2015, 100 : 52 - 53
  • [24] Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency
    Gian Matteo Rigolin
    Pier Paolo Olimpieri
    Valentina Summa
    Simone Celant
    Lydia Scarfò
    Lucia Tognolo
    Maria Pia Ballardini
    Antonio Urso
    Mariarosaria Sessa
    Silvia Gambara
    Francesca Cura
    Monica Fortini
    Paolo Ghia
    Antonio Cuneo
    Pierluigi Russo
    Blood Cancer Journal, 13
  • [25] Long-Term Follow-up, Up to 7 Years, in the RESONATE-2 Study of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL)
    Burger, Jan
    Barr, Paul
    Owen, Carolyn
    Robak, Tadeusz
    Tedeschi, Alessandra
    Bairey, Osnat
    Hillmen, Peter
    Coutre, Steve
    Devereux, Stephen
    Grosicki, Sebastian
    McCarthy, Helen
    Li, Jianyong
    Offner, Fritz
    Moreno, Carol
    Dai, Sandra
    Szoke, Anita
    Dean, James P.
    Kipps, Thomas J.
    Ghia, Paolo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S316 - S316
  • [26] Relative efficacy of systemic treatments for patients with relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis according to 17p deletion/TP53 mutations
    Kim, Jinchul
    Cho, Jinhyun
    Lim, Joo Han
    Lee, Moon Hee
    BLOOD RESEARCH, 2025, 60 (01)
  • [27] ANALYSIS OF TP53 MUTATION IN A LARGE COHORT OF CLL PATIENTS BEFORE FIRST-LINE TREATMENT: ANALYSIS OF THE GENETIC PROFILE WITHIN THE CLL4 TRIAL (F vs FC) OF THE GCLLSG
    Zenz, T.
    Denzel, T.
    Haebe, S.
    Winkler, D.
    Buehler, A.
    Busch, R.
    Eichhorst, B.
    Hallek, M.
    Doehner, H.
    Stilgenbauer, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 216 - 216
  • [28] Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Senapati, Jayastu
    Burger, Jan A.
    Borthakur, Gautam
    Takahashi, Koichi
    Estrov, Zeev E.
    Konopleva, Marina
    Sasaki, Koji
    Kadia, Tapan M.
    Pemmaraju, Naveen
    Daver, Naval
    Jabbour, Elias
    DiNardo, Courtney D.
    Alvarado, Yesid
    Yilmaz, Musa
    Bose, Prithviraj
    Ohanian, Maro
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Nassar, Sameh
    Garg, Naveen
    Hwang, Hyunsoo
    Wang, Xuemei
    Cruz, Nichole
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop
    Gandhi, Varsha
    Wierda, William G.
    BLOOD, 2022, 140
  • [29] Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial
    Zenz, Thorsten
    Haebe, Sonja
    Denzel, Tina
    Mohr, Julia
    Winkler, Dirk
    Buehler, Andreas
    Sarno, Antonio
    Groner, Silja
    Mertens, Daniel
    Busch, Raymonde
    Hallek, Michael
    Doehner, Hartmut
    Stilgenbauer, Stephan
    BLOOD, 2009, 114 (13) : 2589 - 2597
  • [30] Long-term follow-up of a phase Ib trial of idelalisib (IDELA) in combination with chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory (R/R) CLL including pts with del17p/TP53 mutation
    Barrientos, Jacqueline Claudia
    Coutre, Steven
    De Vos, Sven
    Flinn, Ian
    Wagner-Johnston, Nina D.
    Schreeder, Marshall T.
    Sharman, Jeff Porter
    Boyd, Thomas E.
    Rai, Kanti Roop
    Leonard, John
    Sorensen, Bess
    Viggiano, Anthony
    Jahn, Thomas Michael
    Furman, Richard R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345